Business · Companies · 2 hrs ago
Daewoong Pharma to build sterile microneedle drug plant in South Korea
South Korean drugmaker Daewoong Pharma is building a sterile microneedle plant at a Daewoong Bio site in Hwaseong, Gyeonggi Province.
Microneedle patches deliver medicine through tiny needles and may make taking treatment more convenient.
The facility is intended to use sterile processes and automated production designed for these patch medicines.
Daewoong plans to make next-generation products there, including a semaglutide candidate for obesity and diabetes.
The company aims to secure GMP approval in the first half of next year so it can supply clinical trials and prepare for commercial production.
The work is meant to create a manufacturing base for potential future commercialization, including globally.
Daewoong Pharma plans to build sterile manufacturing facilities for microneedle medicines at a plant in Hwaseong, South Korea.
The company aims to obtain Good Manufacturing Practice approval by the first half of 2027.
The facility is intended to support clinical medicine supply and provide a basis for commercial production.
It will be designed for patch medicines, including a semaglutide candidate for obesity and diabetes treatment.
- Who
- Daewoong Pharma.
- What
- It plans to build sterile manufacturing infrastructure for microneedle medicines.
- When
- The company announced the plan on October 14, 2026, and aims for GMP approval by the first half of 2027.
- Where
- Daewoong Bio’s Plant 3 in Hyangnam, Hwaseong, Gyeonggi Province, South Korea.
- Why
- To supply clinical medicines reliably and establish a basis for commercializing next-generation patch medicines.
This story does not have two clearly opposing sides.
Daewoong Pharma announced plans to build microneedle manufacturing infrastructure at Daewoong Bio’s Plant 3 in Hwaseong.
The company aims to complete GMP approval for the facility.
- Location
- Daewoong Bio Plant 3, Hyangnam, Hwaseong, Gyeonggi Province
- GMP approval target
- First half of 2027
- Drug candidate
- DWRX5003, a semaglutide-based candidate for obesity and diabetes treatment
- Technology
- CLOPAM®, Daewoong Therapeutics’ microneedle technology
1 source
Related
South Korea’s KOSPI rises 2.13% after sharp fall
1 hr ago · 3 sources
South Korean pipe stocks jump on Alaska LNG investment remarks
1 hr ago · 3 sources
South Korea’s Kospi plunges as chip shares sell off
1 hr ago · 4 sources
Shinhan agrees to buy 77% of Lotte Insurance for 693.3 billion won
1 hr ago · 4 sources
What people are saying
For innovative formulations such as microneedles, the top priority is to demonstrate the highest level of sterility and quality under strict GMP standards.
We will build the sterile automated manufacturing infrastructure without disruption and establish a basis for the global commercialization of our next-generation pipeline.